The purpose of this study is to determine how well participants with stage II-III
HER2-positive breast cancer respond to pre-operative treatment using one of two different
combinations of drugs.
Drugs and Combinations used:
- Paclitaxel, Pertzumab and Margetuximab (Margenza)
- Paclitaxel, Pertzumab and Trastuzumab (Herceptin)
Phase:
Phase 2
Details
Lead Sponsor:
Dana-Farber Cancer Institute
Collaborators:
MacroGenics Translational Breast Cancer Research Consortium